Targeted drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control
Not yet recruiting
This study tests a new drug, becotatug vedotin, combined with an immunotherapy (PD-1 inhibitor) in adults with advanced head and neck squamous cell carcinoma that cannot be surgically removed. The drug targets a protein called EGFR on cancer cells and delivers a toxin directly to…
Phase: PHASE2 • Sponsor: Feng Liu • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC